Second-Line treatment of small-cell lung cancer :The case for systemic chemotherapy

ONCOLOGY

Volumn 17, Issue 2, 2003, Pages

  Eckardt, John R ^a  

^a ST JOHN S MERCY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER STAGING; CLINICAL TRIAL; HUMAN; LUNG TUMOR; REVIEW; RISK FACTOR; SMALL CELL CARCINOMA; TUMOR RECURRENCE; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RISK FACTORS; UNITED STATES;

EID: 0038142800     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23- 47, 2002.
2. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 49:33-64, 1, 1999.
3. Ries LAG, Hankey BF, Miller BA, et al: SEER Cancer Statistics Review, 1973-19S8. Be- thesda, Md, National Institutes of Health, 1991.
4. Pujol JL, Daures JP, Riviere A, et al: Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small- cell lung cancer: A French Federation of Cancer Institutes multicenter phase III randomized study. J Nail Cancer Inst 93:300-308, 2001.
5. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992.
6. Urban T, Chastang C, Lebas FX, et al: The addition of cisplatin to cyclophosphamide- doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group. Cancer 86:2238-2245, 1999.
7. Spiro SG, Souhami RL, Geddes DM, et al: Duration of chemotherapy in small cell lung cancer: A Cancer Research Campaign trial. Br J Cancer 59:578-583, 1989.
8. Kosmidis PA, Samantas E, Fountzilas G, et al: Cisplatin/etoposide versus carboplatin/ etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 21(suppl 6):23-30, 1994.
9. Girling DJ: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped mul-ticentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 348:563-566, 1996.
10. von Pawel J, Gatzemeier U, Pujol JL, et al: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19:1743-1749, 2001.
11. Depierre A, von Pawel J, Hans K, et al: Evaluation of topotecan (Hycamtin) in relapsed small cell lung cancer (SCLC). A multicenter phase II study. Ling Cancer 18(suppl I):35, 1997.
12. Eckardt J, Gralla R, Palmer MC, et al: Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): A phase II study. Ann Oncol 7(suppl 5): 107, 1996.
13. Cesano A, Lane SR, Poulin R, et al: Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. IntJOncol 15:1233-1238, 1999.
14. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15:2090-2096, 1997.
15. Stephens RJ, Hopwood P, Girling DJ: Defining and analysing symptom palliation in cancer clinical trials: A deceptively difficult exercise. Br J Cancer 79:538-544, 1999.
16. von Pawel J, Schiller JH, Shepherd FA, et al: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658-667, 1999.
17. Kotalik J, Yu E, Markman BR, et al: Practice guideline on prophylactic cranial irradiation in small-cell lung cancer. Int J Radial Oncol Biol Phys 50:309-316, 2001.
18. Fields SZ, Eckardt JR, Zhang L, et al: Efficacy of reduced dose of IV topotecan (T) in relapsed small cell lung cancer (SCLC) patients (abstract 26). Lung Cancer 29(suppl 1):I0, 2000.
19. Koschel R, Huber RM, Gatzemeier U, et al: Topotecan in second-line treatment of small cell lung cancer reduced toxicity with individualized therapy (abstract 136). Lung Cancer 29(suppl I):42, 2000.
20. Ogawara M, Negoro S, Nishiwaki Y, et al: Phase II study of topotecan (TOP) for relapsed small cell lung cancer (SCLC) (abstract 129). Lung Cancer 29(suppl 1):40, 2000.
21. Montazeri A, Gillis CR, McEwen J: Quality of life in patients with lung cancer: A review of literature from 1970 to 1995. Chest 113:467- 481, 1998.
22. Osoba D, Murray N, Gelmon K, et al: Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy. Oncology 8:61-69 (incl discussion), 1994.
23. Ruckdeschel JC, Piantadosi S: Quality of life in lung cancer surgical adjuvant trials. Che'st 106(suppl 6):324S-328S, 1994.
24. Ganz PA, Lee JJ, Siau J: Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 67:3131-3135, 1991.
25. Bernhard J, Flechtner H, Havemann K, et al: Quality-of-life (QL) assessment in Swiss and German multicenter randomized phase III trial for small cell lung cancer (SCLC): Intercultural comparison of QL-questionnaire (abstract 10.32). Lung Cancer 4(suppl 1):AI88, 1988.
26. Hurny C, Bernhard J, Joss R, et al: "Fatigue and malaise" as a quality-of-life indicator in small-cell lung cancer patients. The Swiss Continued on page 191. Group for Clinical Cancer Research (SAKK). Support Care Cancer 1:316-320, 1993.
27. Wolf M, Pritsch M, Drings P et al: Standard vs palliation chemotherapy in metastatic small cell lung cancer: An analysis on treatment efficacy and quality of life. Lung Cancer Il(suppI):S92, 1994.
28. Flechtner H, Holle R, Heim ME, et al: Quality of life assessment in small cell lung cancer: Results from three consecutive German multicentre randomized trials. Qual Life Res 2:63, 1993.
29. Bunn PA, Carney DN: Overview of chemotherapy for small cell lung cancer. Sem'm Oncol 24(suppl 7):S7-69-S7-74, 1997.
30. Zochbauer-Muller S, Pirker R, Huber H: Treatment of small cell lung cancer patients. Ann Oncol 10(suppl 6):83-91, 1999.
31. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987.
32. Tan EH, Ang PT: Resolution of superior vena cava obstruction in small cell lung cancer patients treated with chemotherapy. Ann Acad Med Singapore 24:812-815, 1995.
33. Sakuragi T, Oshita F, NagashimaS, et al: Retrospective analysis of the treatment of patients with small cell lung cancer showing poor performance status. Jpn J Clin Oncol 26: 128-133, 1996.
34. Kelly K: New chemotherapy agents for small cell lung cancer. Chest 117(suppl 1): 156S- 162S, 2000.
35. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15, 1993.
36. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of ace or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999.
37. Abrams J, Doyle LA, Aisner J: Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol 15:261-277, 1988.
38. Ginsberg RJ, Vokes EE, Raben A: Non- small cell lung cancer, in DeVita VT Jr. Hell- man S, Rosenberg SA (eds): Cancer: Principles &Practice of Oncology, 5th ed, pp 858-911. Philadelphia, Lippincott-Raven, 1997.
39. Sandler AB: Irinotecan in small-cell lung cancer: The US experience. Oncology 15:11-12, 2001.
40. DeVore RF, Blanke CD, Denham CA, et al: Phase II study of irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC) (abstract 1736). Proc Am Soc Clin Oncol 17:451a, 1998.
41. Furuse K, Kubota K, Kawahara M, et al: Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology 53:169-172, 1996.
42. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al: Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 29A:1720-I722, 1993.
43. Masters GA, Declerck L, Blanke CD, et al: Gemcitabine in refractory or relapsed small cell lung cancer (SCLC)-E1597: An ECOG Phase II Trial (abstract 2070). Proc Am Soc Clin Oncol 19:527a, 2000.
44. van der Lee I, Smit EF, van Putten JW, et al: Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol 12:557-561, 2001.
45. Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 30A: 1058-1060, 1994.
46. Nakamura H, Azuma M, Miyagi K, et al: A pilot study of docetaxel (TXT) as salvage chemotherapy in small cell lung cancer (SCLC) (abstract 2872). Proc Am Soc Clin Oncol 20:280b, 2001.
47. Kakolyris S, Mavroudis D, Tsavaris N, et al: Paclitaxel in combination with carbo- platin as salvage treatment in refractory small- cell lung cancer (SCLC): A multicenter phase II studyTdnn Oncol 12:193-197, 2001.
48. Groen HJ, Fokkema E, Biesma B, et al: Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: A non-cross-resistant schedule. J Clin Oncol 17:927-932, 1999.
49. Sculier JP, Klastersky J, Libert P, et al: A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potential or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small cell lung cancer. Lung Concur 6:110-118, 1990.
50. Shepherd FA, Evans \VK, MacCormick R, et al: Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 71:941-944, 1987.
51. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992.
52. Nakanishi Y, Takayama K, Takano K, et al: Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol 22:399-402, 1999.
53. Ando M, Kobayashi K, Yoshioka H, et al: Weekly administration of irinotecan (CPT- II) plus cisplatin (CDDP) for refractory or relapsed small cell lung cancer (SCLC) (abstract 1273). Proc Am Soc Clin Oncol 20:319a, 2001.
54. Iaffaioli RV, Facchini G, Tortoriello A, et al: Phase I study of vinorelbine and paclitaxel in small-cell lung cancer. Cancer Chemother Pharmacol 41:86-90, 1997.
55. Domine M, Larriba JG, Morales S, et al: Gemcitabine and paclitaxel as second line treatment in small cell lung cancer (SCLC). A multicentric phase II study (abstract 1263). Proc Am Soc Clin Oncol 20:3I7a, 2001.